Breast imaging with fluorine-18-FDG PET: quantitative image analysis.

UNLABELLED This study evaluated various quantitative criteria for analysis of breast imaging with PET using the radiolabeled glucose analog 18F-fluorodeoxyglucose (FDG). METHODS In a prospective study, 73 patients with abnormal mammography or palpable breast masses scheduled for biopsy were investigated with PET. A total of 97 breast tumors were evaluated by histology, including 46 benign and 51 malignant tumors. Using a whole-body PET scanner, attenuation-corrected images were acquired between 40 and 60 min after tracer injection. For Patlak analysis, dynamic data acquisition was obtained in 24 patients. To differentiate between benign and malignant breast tumors, receiver operating characteristic curves were calculated using incrementally increasing threshold values for tumor/ nontumor ratios based on average and maximum activity values per region of interest, standardized uptake values (corrected for partial volume effect, normalized to blood glucose, partial volume effect and blood glucose, using the lean body mass as well as the body surface area) and calculating the FDG influx rate (K) assessed by Patlak analysis. RESULTS Quantification of FDG uptake in breast tumors provided objective criteria for differentiation between benign and malignant tissue with similar diagnostic accuracy as compared with visual analysis. Applying correction for partial volume effect and normalization by blood glucose yielded the highest diagnostic accuracy. CONCLUSIONS These quantitative methods provided accurate evaluation of PET data for differentiating benign from malignant breast tumors. Quantitative assessment is recommended to complement visual image interpretation with the potential benefit of reduced interobserver variability.

[1]  R. Brooks,et al.  PET quantitation: blessing and curse. , 1988, Journal of Nuclear Medicine.

[2]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  D. Lee,et al.  Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  E. Hoffman,et al.  Quantitation in Positron Emission Computed Tomography: 1. Effect of Object Size , 1979, Journal of computer assisted tomography.

[5]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  M Schwaiger,et al.  Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  R L Wahl,et al.  Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. , 1993, Radiology.

[8]  R L Wahl,et al.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1991, Radiology.

[9]  K. Hamacher,et al.  Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  M E Phelps,et al.  The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. , 1992, Annals of surgery.

[11]  J. Keyes SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  E. Rota Kops,et al.  The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Heikki Joensuu,et al.  Florodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors , 1988 .

[14]  A. Alavi,et al.  Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  R L Wahl,et al.  Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. , 1992, Radiology.

[16]  H. Schelbert,et al.  Measurement of regional glucose metabolic rates in reperfused myocardium. , 1991, The American journal of physiology.

[17]  C. Metz Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.

[18]  H. Minn,et al.  Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. , 1988, Cancer.

[19]  J M Hoffman,et al.  Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  J L Sunshine,et al.  Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. , 1993, Radiology.

[22]  M. Ito,et al.  Imaging of breast cancer with [18F]fluorodeoxyglucose and positron emission tomography. , 1989, Journal of computer assisted tomography.

[23]  M Schwaiger,et al.  Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P Schmidlin,et al.  Recurrence of colorectal tumors: PET evaluation. , 1989, Radiology.

[25]  G. Hortobagyi,et al.  Positron emission tomography with fluorine‐18‐deoxyglucose in the detection and staging of breast cancer , 1993, Cancer.

[26]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[27]  L M Hamberg,et al.  The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  G. van Kaick,et al.  PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Michael E. Phelps,et al.  Cancer Detection with Whole‐Body PET Using 2‐[18F]Fluoro‐2-Deoxy‐D-Glucose , 1993, Journal of computer assisted tomography.

[30]  J. Holden,et al.  Sensitivity of myocardial fluorodeoxyglucose lumped constant to glucose and insulin. , 1991, The American journal of physiology.

[31]  A. Wolf,et al.  Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[33]  M. Phelps,et al.  Quantitating tumor glucose metabolism with FDG and PET. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.